Latest Inflammatory bowel disease Stories
OAKLAND, Calif., Aug. 17, 2011 /PRNewswire-USNewswire/ -- The Kenneth Rainin Foundation (KRF) announced today the establishment of its Breakthrough Awards Program, which is designed to enable investigators to further their Inflammatory Bowel Disease (IBD) research and increase the likelihood of a breakthrough discovery. These grants are awarded to existing KRF-funded Innovator Award recipients that have demonstrated significant research progress along their proposed "proof of principle"...
SAN DIEGO and FRANKLIN LAKES, N.J., Aug. 15, 2011 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostics company that is part of Nestle Health Science, and the Medco Research Institute®, LLC, a wholly-owned subsidiary of Medco Health Solutions, Inc. (NYSE: MHS), today announced that they have entered into a collaboration to evaluate the use of Prometheus' Thiopurine Metabolite (PTM) testing for optimizing dosing of 6 mercaptopurine (6MP) or azathioprine...
HORSHAM, Pa., July 25, 2011 /PRNewswire/ -- American Idol contestant Casey Abrams is launching a national disease awareness campaign, IBD Icons, to let people know that living with an inflammatory bowel disease (IBD) does not have to stop them from pursuing their dreams. Starting today, people living with IBD will have the opportunity to share how they are achieving their personal goals despite the challenges of their disease at www.IBDIcons.com for a chance to win the title of "IBD Icon"....
HORSHAM, Pa., July 21, 2011 /PRNewswire/ -- Janssen Biotech, Inc., formerly Centocor Ortho Biotech Inc., announced today that the Gastrointestinal Drugs Advisory Committee (GIDAC) of the U.S. Food and Drug Administration (FDA) recommended the approval of REMICADE® (infliximab) for the treatment of moderately to severely active ulcerative colitis (UC) in pediatric patients who have had an inadequate response to conventional therapy. REMICADE® was designated orphan drug status by the...
Westie Foundation of America reports preliminary research progress in dog breed's health and potential implicationsThe Westie Foundation of America (WFA) announced today preliminary findings in two major studies involving the health of West Highland White Terriers also known as Westies. Findings in these and other studies of Westies and other dogs may hold answers for similar human conditions like Inflammatory Bowel Disease (IBD). The studies are jointly funded by the WFA and the AKC Canine...
NEW YORK, July 12, 2011 /PRNewswire-USNewswire/ -- The Crohn's & Colitis Foundation of America today announced that it has opened enrollment for CCFA Partners, a comprehensive Internet-based registry designed to study thousands of patients with Crohn's disease or ulcerative colitis under a single research initiative. These chronic and often painful digestive diseases, collectively known as inflammatory bowel diseases (IBD), affect over 1.4 million Americans. Unlike prior research,...
HEIDELBERG, Germany, June 22, 2011 /PRNewswire/ -- - Primary Endpoint Met Lipid Therapeutics, a biotechnology company focused on novel treatments for inflammatory bowel disease, today announced positive topline results from a Phase IIb clinical trial with its lead product, LT-02, in patients with ulcerative colitis. LT-02 is a controlled release formulation of phosphatidylcholine that has been specifically designed to treat ulcerative colitis by improving the barrier...
UPPER SADDLE RIVER, N.J., June 14, 2011 /PRNewswire/ -- WellApps, Inc. announced today the newest release of GI Monitor, its symptom tracking app for (IBD) Crohn's and Ulcerative Colitis. Co-Founder Edward Shin, MD, says, "We're particularly excited about the new release since GI Monitor has recently quadrupled its user-base. This scale is providing some powerful real-time data and we know what an engaged mobile community can mean for patients." One of those patients is Brett Shamosh,...
The first study of the social and ethical issues associated with a provocative approach to treatment for ulcerative colitis has found that the majority of potential patients are eager for what is now called "fecal microbiota transplantation" to become available, although many have concerns about donor selection, screening, and methods of delivery.Bacterial aggregates derived from fecal matter have been used sporadically to treat gastrointestinal disease for more than 50 years. These...
Researchers from Boston University School of Medicine (BUSM), along with clinicians from Boston Medical Center (BMC), have found gastroenterologist knowledge of the appropriate immunizations to recommend to the inflammatory bowel disease (IBD) patient is limited. These findings, which currently appear on-line in Inflammatory Bowel Diseases, may be the primary reason why the majority of gastroenterologists believe that the primary care provider (PCP) should be responsible for...
